BARDA Awards $500M In Project NextGen Funding For Novel Nasal Spray Or Oral Pill COVID-19 Vaccines

Healthcare Finance News (6/14, Lagasse) reported, “The Biomedical Advanced Research and Development Authority (BARDA) is setting aside up to $500 million in Project NextGen funding to plan and execute multiple Phase 2b clinical trials evaluating novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19.” As much as “$453 million will go to Vaxart of San Francisco, California, for developing an oral pill vaccine candidate.” Additionally, around “$34 million will go to Castlevax, part of the Mount Sinai Health System in New York City, developing an intranasal vaccine candidate, CVAX-01. And roughly $40 million is set to be awarded to Cyanvac of Athens, Georgia, developing an intranasal vaccine candidate, CVXGA.”